Metabolic Effectiveness of Extracorporeal Shockwave on Abdominal Adiposity (NCT07686601) | Clinical Trial Compass
By InvitationNot Applicable
Metabolic Effectiveness of Extracorporeal Shockwave on Abdominal Adiposity
Egypt90 participantsStarted 2026-06-01
Plain-language summary
Egyptian Ministry of Health and Population's Preventive Sector, have named obesity as one of the top contributors to the national mortality and morbidity. Abdominal obesity is a strong predictor of metabolic disorders and premature mortality. Visceral fat is metabolically active and sensitive for lipolysis, unless it is more insulin resistant. It is well-known that overweight and/ or obesity is associated with overactivated proinflammatory cytokines those overactivated inflammatory process thus led to organs dysfunction across persistent low-grade inflammations . Recently, extracorporeal shock wave represents a promising, non-invasive management strategy supporting the treatment of a variety of conditions related to plastic surgery. As well, it displayed a good safety profile with no serious adverse events .
The need of this study develops from the lack in the quantitative knowledge and information regarding overall metabolic effectiveness of the Extracorporeal Shockwave on abdominal adiposity.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age \> 18years old.
. All of them suffered from abdominal obesity.
. All have waist/ hip ratio of \> 0.85 and their waist circumference \> 90 cm.
Exclusion criteria
. Patients with diabetes mellitus, heart and/ or vascular, renal, hepatic, pulmonary, neurological, psychological, and or mental disorders are excluded.
. Patients who had autoimmune diseases were excluded.
. Patients with hypertension, metal or electronic implants were excluded.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is testing extracorporeal shockwave therapy specifically on abdominal fat — can you explain how this physical treatment is thought to affect metabolic markers like my HbA1c and lipid levels, and whether that mechanism makes sense for my situation?
2The trial is measuring FIB4, which is a liver health marker — does my current liver health make this trial a good or poor fit for me, and is there something about my abdominal obesity that might be affecting my liver that we should already be addressing?
3Since this study is 'enrolling by invitation only,' can you tell me whether I would even be eligible to be considered, and who is running or sponsoring this trial so we can find out how invitations are issued?
4This trial is listed as Phase NA, which often applies to device or non-drug studies — does that mean there's less safety and efficacy data available compared to a standard drug trial, and what is actually known so far about shockwave therapy for abdominal fat reduction?
5Are there standard treatments — like lifestyle interventions, medication, or other approaches — that might address my abdominal obesity and metabolic concerns more reliably right now, rather than waiting to see if this experimental approach pans out?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
FIB4
Timeframe: 1. At Pre-procedure, at the first day of the study, 2. Post-treatment = means by the end of the 12 weeks of the study procedures, 3. Follow up at 6 months post-treatment procedures: 6 months after the 12 weeks of the study program.
2
Hb A1c
Timeframe: 1. At Pre-procedure, at the first day of the study, 2. Post-treatment = means by the end of the 12 weeks of the study procedures, 3. Follow up at 6 months post-treatment procedures: 6 months after the 12 weeks of the study program.
3
Lipid profile
Timeframe: 1. At Pre-procedure, at the first day of the study, 2. Post-treatment = means by the end of the 12 weeks of the study procedures, 3. Follow up at 6 months post-treatment procedures: 6 months after the 12 weeks of the study program.
. Patients, who have intra-abdominal mesh and/ or unrepaired abdominal hernia were excluded.
. Patients who have cancer were excluded.
. Patients who have scars, open lesions and wounds at treatment area were excluded.
. Patients who have any intervention to lose weight or body contouring within the last 6 months (diet, exercise or body contouring devices) were excluded.
. Patients who received pharmacological drugs for controlling obesity were excluded.